Hyperbaric oxygen therapy is one of the most studied complementary medical treatments — its modern clinical use spans more than 80 years and the underlying physics is settled.
This guide explains exactly how HBOT works at the physiological and cellular level, what the evidence supports, and where the science is still developing.
The Basic Principle: Henry's Law
HBOT is built on Henry's Law of physics — the amount of gas dissolved in a liquid is proportional to the partial pressure of that gas above the liquid.
In practical terms:
- At normal atmospheric pressure (1 ATA) breathing room air (21% oxygen), blood carries about 0.3 mL of dissolved oxygen per 100 mL of plasma
- At 2.0 ATA breathing 100% oxygen, dissolved plasma oxygen increases to approximately 4.4 mL per 100 mL — a roughly 15-fold increase
- At 3.0 ATA breathing 100% oxygen, dissolved oxygen reaches approximately 6.0 mL per 100 mL
This dissolved oxygen bypasses hemoglobin entirely. It travels freely in blood plasma — critical because many disease states involve compromised blood flow where hemoglobin-bound oxygen cannot reach tissues but plasma-dissolved oxygen still can.
The UHMS 13th Edition Indications (2024) explicitly grounds each of the 14 approved indications in this physiologic mechanism.
Primary Mechanisms of Action
1. Hyperoxia and Tissue Oxygenation
The immediate effect of HBOT is dramatically increased tissue oxygen levels.
Oxygen diffusion distance from capillaries triples or quadruples at 2.0+ ATA. Tissues with compromised blood supply — diabetic wounds, radiation-damaged tissue, crush injuries — receive oxygen they otherwise cannot access.
Hypoxic tissues resume normal metabolic function, ATP production rises, and cellular repair pathways activate. This is the most directly observable HBOT mechanism and the foundation for the wound-healing indications.
2. Angiogenesis (New Blood Vessel Formation)
HBOT stimulates new blood vessel growth across the treatment course.
Paradoxically, hyperbaric oxygen activates hypoxia-inducible factor 1-alpha (HIF-1a) during the reperfusion phase. VEGF (vascular endothelial growth factor) production increases, driving formation of new capillary networks over 20-40 sessions.
The Cochrane HBOT for Chronic Wounds review (2024) identified angiogenesis as the primary mechanism underlying HBOT's benefit in chronic wounds and delayed radiation injury.
3. Stem Cell Mobilization
HBOT triggers stem cell release from bone marrow into circulation.
A Thom et al. 2006 study in the American Journal of Physiology found that a single HBOT session doubled circulating CD34+ stem cells, and 20 sessions increased counts up to 8-fold. The mechanism operates through nitric oxide signaling in bone marrow.
These stem cells migrate to damaged tissues and contribute to repair, particularly in chronic wound and radiation injury indications.
4. Anti-Inflammatory Effects
HBOT modulates the immune system and reduces inflammation.
It downregulates pro-inflammatory cytokines including TNF-alpha, IL-1, and IL-6, while upregulating anti-inflammatory mediators. Neutrophil adhesion to vessel walls decreases.
The 2024 BMC Neurology meta-analysis on acute ischemic stroke measured inflammatory markers across 493 patients and found HBOT modestly modulated several markers, though effect sizes varied widely between trials. See the stroke recovery evidence atlas for the full investigational evidence breakdown.
5. Antimicrobial Activity
High-pressure oxygen is directly toxic to certain bacteria.
Anaerobic bacteria — including the Clostridium species responsible for gas gangrene — cannot survive in high-oxygen environments. HBOT also enhances white blood cell killing ability through the oxidative burst mechanism. See the gas gangrene evidence atlas for the full study-by-study evidence breakdown.
This is why HBOT is FDA-cleared for gas gangrene (clostridial myositis and myonecrosis), necrotizing soft-tissue infections, and chronic refractory osteomyelitis — three of the 14 indications in CMS NCD 20.29.
6. Neuroplasticity
HBOT can stimulate brain repair and new neural connections, particularly in the chronic post-injury setting.
It increases BDNF (brain-derived neurotrophic factor) production, promotes synaptogenesis, reduces neuroinflammation, and improves cerebral blood flow.
A landmark Boussi-Gross et al. 2013 study in PLOS One showed HBOT induced significant neuroplasticity in stroke patients even years after their initial event. The 2025 Scientific Reports long COVID trial extended this finding to post-viral cognitive dysfunction.
7. Senolytic and Telomere Effects
A 2020 Aging study by Hachmo et al. reported that 60 HBOT sessions in healthy adults aged 64+ lengthened telomeres by up to 20% and cleared senescent cells by up to 37%.
These findings sparked the anti-aging HBOT market, but the study is small (35 subjects) and has not yet been independently replicated at scale. The mechanism remains hypothesis-generating rather than confirmed clinical practice.
The Treatment Process
Pressurization Phase (5-15 minutes)
Chamber pressure gradually increases to treatment level — typically 2.0-2.5 ATA for on-label indications.
Patients feel ear fullness similar to descending in an airplane. Equalization techniques — swallowing, jaw movement, gentle Valsalva — relieve the pressure as documented in the Divers Alert Network guide (2023).
Air temperature inside the chamber rises a few degrees due to compression.
Treatment Phase (60-90 minutes)
Patients breathe 100% oxygen at full treatment pressure. Blood plasma oxygen reaches therapeutic concentrations and the cellular mechanisms activate.
Most patients rest, sleep, watch media, or listen to music during this phase. Longer protocols include 5-minute air breaks every 20-30 minutes to reduce oxygen toxicity risk per the Cochrane Oxygen Toxicity review (2023).
Depressurization Phase (5-15 minutes)
Chamber pressure gradually returns to normal atmospheric pressure. Air cools slightly. Patients feel ear popping similar to airplane ascent.
No immediate side effects for most patients. Most can drive themselves home and return to normal activities the same day.
Clinical Evidence
FDA-Cleared Conditions (Strong Evidence)
The 14 indications listed in CMS NCD 20.29 and the UHMS 13th Edition (2024):
- Air or gas embolism
- Carbon monoxide poisoning
- Gas gangrene (clostridial myositis and myonecrosis)
- Crush injury and compartment syndrome
- Decompression sickness
- Diabetic wounds of the lower extremity (Wagner grade 3+)
- Exceptional blood loss anemia
- Intracranial abscess
- Necrotizing soft-tissue infections
- Chronic refractory osteomyelitis
- Delayed radiation injury (soft tissue and bony necrosis)
- Compromised skin grafts and flaps
- Acute thermal burn injury
- Idiopathic sudden sensorineural hearing loss
These are the conditions Medicare and most commercial insurers reimburse.
Emerging Applications (Growing Evidence, Not FDA-Cleared)
- Long COVID: a 2025 Scientific Reports trial by Zilberman-Itskovich et al. reported 40 sessions improved cognition, sleep, and quality of life with benefits persisting at 1 year
- Traumatic brain injury: ongoing trials including the federally registered NCT02407028 study and the $28M USF Health veteran trial launched 2024-2025
- Stroke recovery: a 2024 BMC Neurology meta-analysis of 493 patients showed improved modified Rankin score with no significant NIHSS change
- PTSD: a 2024 Frontiers in Neurology systematic review of 393 subjects reported dose-dependent symptomatic improvement with 30-39% of high-dose subjects experiencing reversible emotional exacerbation
- Anti-aging: the Hachmo 2020 Aging study reported telomere and senescent-cell effects but the result has not yet been independently replicated
The FDA Safety Communication (2021, reaffirmed 2024) is explicit: no HBOT device has been cleared for these emerging indications. Patients pursuing them should know they're paying cash for treatments with promising but unsettled evidence.
Frequently Asked Questions
How quickly does HBOT start working?
Cellular effects begin during the first session — dissolved plasma oxygen rises immediately. Clinical improvements typically appear after 10-20 sessions for most indications. The full benefit of 40-session protocols develops gradually across the course. The 2025 Scientific Reports long COVID trial reported sleep and energy improvements within the first 10-15 sessions, with cognitive gains continuing to develop through session 40.
Is HBOT just breathing oxygen?
No. HBOT combines two critical elements — increased atmospheric pressure AND concentrated oxygen. Simply breathing pure oxygen at normal pressure (normobaric oxygen) produces far less dissolved plasma oxygen than HBOT at 2.0+ ATA. The combination of pressure and oxygen is what creates the therapeutic environment, per Henry's Law and the UHMS 13th Edition Indications (2024).
Can HBOT regrow brain cells?
HBOT does not directly regrow neurons, but it stimulates neuroplasticity — the brain's ability to form new connections and reorganize existing pathways. The Boussi-Gross 2013 PLOS One study demonstrated this mechanism in chronic stroke patients, and the 2025 long COVID Scientific Reports trial extended it to post-viral cognitive dysfunction.
How is HBOT different from an oxygen bar?
Oxygen bars deliver supplemental oxygen at normal atmospheric pressure through a nasal cannula. This raises inspired oxygen percentage but does not meaningfully increase plasma-dissolved oxygen. HBOT uses sealed pressurized chambers at 1.5-3.0 ATA, which Henry's Law requires for the dramatic increase in dissolved oxygen. The therapeutic mechanisms of HBOT depend entirely on pressurization. The FDA Safety Communication (2021) warns that any commercial product not delivering medical-grade pressurized oxygen does not produce HBOT effects.
Does HBOT have long-lasting effects?
Yes, for many indications. The 2025 long COVID Scientific Reports trial found improvements persisting at 1 year post-treatment. Angiogenesis creates permanent structural improvements in tissue blood supply. However, some benefits may gradually diminish without maintenance sessions, particularly for conditions involving ongoing inflammation or degeneration. The Hachmo 2020 Aging study did not include follow-up beyond the immediate post-treatment period, so the durability of telomere effects is unknown.
Find HBOT Centers Near You
Browse our complete directory of UHMS-accredited HBOT centers to find a verified facility near you and confirm which indications they treat.
-- The HBOT Finder Team
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. The 14 indications in CMS NCD 20.29 are FDA-cleared and insurance-reimbursable. Off-label uses including long COVID, TBI, PTSD, and anti-aging carry promising research but are not FDA-cleared and not covered by insurance per the FDA Safety Communication (2021).
Editorial Disclosure: HBOT Finder maintains editorial independence. We do not accept paid placements in our directory.